{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:00Z","timestamp":1791919440385,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00520-023-08083-w","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:03:30Z","timestamp":1697004210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data"],"prefix":"10.1007","volume":"31","author":[{"given":"Deniz Can","family":"Guven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enes","family":"Erul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"Kaygusuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baran","family":"Akagunduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"issue":"2","key":"8083_CR1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"1","key":"8083_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95","journal-title":"J Immunother Cancer"},{"issue":"9","key":"8083_CR3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"key":"8083_CR4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.05.022","volume":"117","author":"J Lemasson","year":"2019","unstructured":"Lemasson J, Cuzzubbo S, Doucet L et al (2019) Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series. Eur J Cancer 117:116\u2013118","journal-title":"Eur J Cancer"},{"key":"8083_CR5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40425-017-0226-5","volume":"5","author":"ME Nader","year":"2017","unstructured":"Nader ME, Myers JN, Gidley PW (2017) Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis. J Immunother Cancer 5:24","journal-title":"J Immunother Cancer"},{"key":"8083_CR6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-016-0114-4","volume":"4","author":"M Zibelman","year":"2016","unstructured":"Zibelman M, Pollak N, Olszanski AJ (2016) Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer 4:8","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8083_CR7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.36401\/JIPO-21-17","volume":"5","author":"JC Page","year":"2022","unstructured":"Page JC, Gidley PW, Nader ME (2022) Audiovestibular Toxicity Secondary to Immunotherapy: Case Series and Literature Review. J Immunother Precis Oncol 5(1):2\u20136","journal-title":"J Immunother Precis Oncol"},{"key":"8083_CR8","doi-asserted-by":"crossref","unstructured":"Rajapakse A, O'Leary C, Gundelach R et al (2020) Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. Oxf Med Case Reports 2020(9):omaa077","DOI":"10.1093\/omcr\/omaa077"},{"key":"8083_CR9","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"8083_CR10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2022.06.049","volume":"173","author":"C Boutros","year":"2022","unstructured":"Boutros C, Peres E, Routier E et al (2022) Severe ototoxicity associated with immune checkpoint inhibitors (ICI) in advanced melanoma. Eur J Cancer 173:204\u2013206","journal-title":"Eur J Cancer"},{"issue":"6","key":"8083_CR11","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","volume":"96","author":"A Vogrig","year":"2021","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B et al (2021) Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. Neurology 96(6):e866\u2013e875","journal-title":"Neurology"},{"issue":"3_suppl","key":"8083_CR12","doi-asserted-by":"crossref","first-page":"286s","DOI":"10.1177\/0145561320940847","volume":"100","author":"AJF Tampio","year":"2021","unstructured":"Tampio AJF, Dhanireddy S, Sivapiragasam A et al (2021) Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma. Ear Nose Throat J 100(3_suppl):286s\u2013291s","journal-title":"Ear Nose Throat J"},{"issue":"6","key":"8083_CR13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/ced.14640","volume":"46","author":"R Godse","year":"2021","unstructured":"Godse R, McGettigan S, Schuchter LM et al (2021) Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1\/anti-CTLA4 therapy. Clin Exp Dermatol 46(6):1111\u20131112","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"8083_CR14","doi-asserted-by":"crossref","first-page":"e001675","DOI":"10.1136\/jitc-2020-001675","volume":"8","author":"S Rosner","year":"2020","unstructured":"Rosner S, Agrawal Y, Sun DQ et al (2020) Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. J Immunother Cancer 8(2):e001675","journal-title":"J Immunother Cancer"},{"issue":"7","key":"8083_CR15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/imt-2019-0206","volume":"12","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Seifert C, Lehmann M et al (2020) Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy 12(7):439\u2013444","journal-title":"Immunotherapy"},{"issue":"6","key":"8083_CR16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/1346-8138.14273","volume":"45","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kambayashi Y, Tanita K et al (2018) HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J Dermatol 45(6):735\u2013737","journal-title":"J Dermatol"},{"issue":"11","key":"8083_CR17","first-page":"E35","volume":"42","author":"JS Choi","year":"2020","unstructured":"Choi JS, Chen M, McQuade JL et al (2020) Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head Neck 42(11):E35-e42","journal-title":"Head Neck"},{"issue":"3","key":"8083_CR18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CJI.0000000000000353","volume":"44","author":"EAT Koch","year":"2021","unstructured":"Koch EAT, Nickel FT, Heinzerling L et al (2021) Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy. J Immunother 44(3):114\u2013117","journal-title":"J Immunother"},{"issue":"33","key":"8083_CR19","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1200\/JCO.2011.41.4359","volume":"30","author":"C Voskens","year":"2012","unstructured":"Voskens C, Cavallaro A, Erdmann M et al (2012) Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 30(33):e356-357","journal-title":"J Clin Oncol"},{"issue":"11","key":"8083_CR20","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1002\/phar.1839","volume":"36","author":"KS Hanna","year":"2016","unstructured":"Hanna KS (2016) A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. Pharmacotherapy 36(11):e183\u2013e188","journal-title":"Pharmacotherapy"},{"issue":"1","key":"8083_CR21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00415-019-09587-4","volume":"267","author":"M De Groot","year":"2020","unstructured":"De Groot M, Compter A, De Langen AJ et al (2020) Susac\u2019s syndrome as an immune-related adverse event after pembrolizumab: a case report. J Neurol 267(1):282\u2013284","journal-title":"J Neurol"},{"issue":"1","key":"8083_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","volume":"256","author":"CD Conrady","year":"2018","unstructured":"Conrady CD, Larochelle M, Pecen P et al (2018) Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol 256(1):187\u2013191","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"8083_CR23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","volume":"6","author":"F Karzai","year":"2018","unstructured":"Karzai F, VanderWeele D, Madan RA et al (2018) Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 6(1):141","journal-title":"J Immunother Cancer"},{"issue":"10","key":"8083_CR24","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s41433-019-0473-4","volume":"33","author":"MJ Dolaghan","year":"2019","unstructured":"Dolaghan MJ, Oladipo B, Cooke CA et al (2019) Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland. Eye (Lond) 33(10):1670\u20131672","journal-title":"Eye (Lond)"},{"issue":"5","key":"8083_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CJI.0000000000000367","volume":"44","author":"SH St\u00fcrmer","year":"2021","unstructured":"St\u00fcrmer SH, Lechner A, Berking C (2021) Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors. J Immunother 44(5):193\u2013197","journal-title":"J Immunother"},{"issue":"1","key":"8083_CR26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma W, Xue R, Zhu Z et al (2023) Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol 12(1):10","journal-title":"Exp Hematol Oncol"},{"key":"8083_CR27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijporl.2020.110401","volume":"138","author":"K Rajput","year":"2020","unstructured":"Rajput K, Edwards L, Brock P et al (2020) Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer. Int J Pediatr Otorhinolaryngol 138:110401","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"8083_CR28","doi-asserted-by":"crossref","unstructured":"Sanchez VA, Shuey MM, PCD Jr (2003) Patient-reported functional impairment due to hearing loss and tinnitus after cisplatin-based chemotherapy. J Clin Oncol 41(12):2211\u20132226","DOI":"10.1200\/JCO.22.01456"},{"issue":"3","key":"8083_CR29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/WAD.0000000000000325","volume":"33","author":"A Chern","year":"2019","unstructured":"Chern A, Golub JS (2019) Age-related Hearing Loss and Dementia. Alzheimer Dis Assoc Disord 33(3):285\u2013290","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"8083_CR30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1242\/dev.107.3.453","volume":"107","author":"KP Steel","year":"1989","unstructured":"Steel KP, Barkway C (1989) Another role for melanocytes: their importance for normal stria vascularis development in the mammalian inner ear. Development 107(3):453\u2013463","journal-title":"Development"},{"key":"8083_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.heares.2014.12.002","volume":"320","author":"MA Mujica-Mota","year":"2015","unstructured":"Mujica-Mota MA, Schermbrucker J, Daniel SJ (2015) Eye color as a risk factor for acquired sensorineural hearing loss: A review. Hear Res 320:1\u201310","journal-title":"Hear Res"},{"issue":"11","key":"8083_CR32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/dneu.22279","volume":"75","author":"H Locher","year":"2015","unstructured":"Locher H, de Groot JC, van Iperen L et al (2015) Development of the stria vascularis and potassium regulation in the human fetal cochlea: Insights into hereditary sensorineural hearing loss. Dev Neurobiol 75(11):1219\u20131240","journal-title":"Dev Neurobiol"},{"issue":"3","key":"8083_CR33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133\u2013150","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"8083_CR34","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 151(11):1206\u20131212","journal-title":"JAMA Dermatol"},{"issue":"7","key":"8083_CR35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773\u2013781","journal-title":"J Clin Oncol"},{"issue":"4","key":"8083_CR36","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 22(4):886\u2013894","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8083_CR37","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.cllc.2019.10.009","volume":"21","author":"K Suresh","year":"2020","unstructured":"Suresh K, Naidoo J (2020) Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer. Clin Lung Cancer 21(3):e169\u2013e170","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"8083_CR38","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","volume":"27","author":"X Bai","year":"2021","unstructured":"Bai X, Hu J, Betof Warner A et al (2021) Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti\u2013PD-1 Monotherapy. Clin Cancer Res 27(21):5993\u20136000","journal-title":"Clin Cancer Res"},{"issue":"18","key":"8083_CR39","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706\u20133714","journal-title":"Cancer"},{"issue":"3","key":"8083_CR40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/imt-2020-0179","volume":"13","author":"FG Dall'Olio","year":"2021","unstructured":"Dall\u2019Olio FG, Rizzo A, Mollica V et al (2021) Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 13(3):257\u2013270","journal-title":"Immunotherapy"},{"issue":"36","key":"8083_CR41","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 39(36):4073\u20134126","journal-title":"J Clin Oncol"},{"issue":"3","key":"8083_CR42","volume":"14","author":"C Sialakis","year":"2022","unstructured":"Sialakis C, Iliadis C, Frantzana A et al (2022) Intratympanic Versus Systemic Steroid Therapy for Idiopathic Sudden Hearing Loss: A Systematic Review and Meta-Analysis. Cureus 14(3):e22887","journal-title":"Cureus"},{"issue":"8","key":"8083_CR43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1017\/S0022215114001595","volume":"128","author":"I Dallan","year":"2014","unstructured":"Dallan I, Fortunato S, Casani AP et al (2014) Long-term follow up of sudden sensorineural hearing loss patients treated with intratympanic steroids: audiological and quality of life evaluation. J Laryngol Otol 128(8):669\u2013673","journal-title":"J Laryngol Otol"},{"issue":"5","key":"8083_CR44","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/01.mao.0000224092.79635.ee","volume":"27","author":"S Kakehata","year":"2006","unstructured":"Kakehata S, Sasaki A, Oji K et al (2006) Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes. Otol Neurotol 27(5):604\u2013608","journal-title":"Otol Neurotol"},{"issue":"2","key":"8083_CR45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/21695717.2018.1442282","volume":"16","author":"R Salvi","year":"2018","unstructured":"Salvi R, Ding D, Jiang H et al (2018) Hidden Age-Related Hearing Loss and Hearing Disorders: Current Knowledge and Future Directions. Hearing Balance Commun 16(2):74\u201382","journal-title":"Hearing Balance Commun"},{"issue":"1","key":"8083_CR46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing P, Zhang F, Wang G et al (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 7(1):341","journal-title":"J Immunother Cancer"},{"issue":"22","key":"8083_CR47","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer. N Engl J Med 378(22):2078\u20132092","journal-title":"N Engl J Med"},{"issue":"20","key":"8083_CR48","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D et al (2021) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med 385(20):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"10212","key":"8083_CR49","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 394(10212):1915\u20131928","journal-title":"The Lancet"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08083-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T10:05:14Z","timestamp":1702548314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08083-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8083"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08083-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Non-available due to use of previously published data in literature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Non-available due to use of previously published data in literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Non-available due to use of previously published data in literature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No writing assistance was taken during the preparation of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Writing assistance"}}],"article-number":"624"}}